Datamonitor views big brand survival in shrinking anti-hormanal cancer market; outlook for Celgene's Revlimed

Strategic lifecycle management has become a critical issue for pharmaceutical companies in the anti-hormanal cancer market, which has traditionally been dominated by a few key brands, suggests independent market analyst Datamonitor.

Anti-hormonal cancer therapies are used predominantly in the treatment of breast and prostate cancer. Despite their limited clinical application, the high incidence of these tumor types translates into significant commercial potential for drug developers. Collectively, the anti-hormonal therapy cancer brands generated sales of $7.0 billion in the seven major pharmaceutical markets in 2009.

However, over the next 10 years the patent expiries of leading anti-hormonal brands, particularly in the USA, will produce a surge of generic products into the market and Datamonitor expects the market to marginally shrink.